Tumor-induced osteomalacia P Florenzano, IR Hartley, M Jimenez, K Roszko, RI Gafni, MT Collins Calcified Tissue International 108, 128-142, 2021 | 122 | 2021 |
Fibrous dysplasia of bone and McCune–Albright syndrome: a bench to bedside review I Hartley, M Zhadina, MT Collins, AM Boyce Calcified tissue international 104, 517-529, 2019 | 70 | 2019 |
Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI) CR Ferreira, ME Hackbarth, SG Ziegler, KS Pan, MS Roberts, DR Rosing, ... Genetics in Medicine 23 (2), 396-407, 2021 | 55 | 2021 |
Targeted FGFR blockade for the treatment of tumor-induced osteomalacia IR Hartley, CB Miller, GZ Papadakis, C Bergwitz, J Del Rivero, JE Blau, ... New England Journal of Medicine 383 (14), 1387-1389, 2020 | 28 | 2020 |
Pheochromocytoma and paraganglioma patients with poor survival often show brown adipose tissue activation Z Abdul Sater, A Jha, A Hamimi, A Mandl, IR Hartley, S Gubbi, M Patel, ... The Journal of Clinical Endocrinology & Metabolism 105 (4), 1176-1185, 2020 | 21 | 2020 |
Autosomal dominant hypocalcemia type 1: A systematic review KL Roszko, LM Stapleton Smith, AV Sridhar, MS Roberts, IR Hartley, ... Journal of Bone and Mineral Research 37 (10), 1926-1935, 2020 | 14 | 2020 |
PTH and FGF23 exert interdependent effects on renal phosphate handling: evidence from patients with hypoparathyroidism and hyperphosphatemic familial tumoral calcinosis treated … D Ovejero, IR Hartley, LF de Castro Diaz, E Theng, X Li, RI Gafni, ... Journal of Bone and Mineral Research 37 (2), 179-184, 2020 | 13 | 2020 |
Diverticular perforation: a fatal complication to forestall in Cushing syndrome ZA Sater, S Jha, R McGlotten, I Hartley, M El Lakis, KA Araque, ... The Journal of Clinical Endocrinology & Metabolism 103 (8), 2811-2814, 2018 | 12 | 2018 |
A cross sectional cohort study of the effects of FGF23 deficiency and hyperphosphatemia on dental structures in hyperphosphatemic familial tumoral calcinosis AE Lee, EY Chu, PJ Gardner, O Duverger, A Saikali, SK Wang, RI Gafni, ... Journal of Bone and Mineral Research Plus 5 (5), e10470, 2021 | 10 | 2021 |
Determination of FGF23 levels for the diagnosis of FGF23‐mediated hypophosphatemia IR Hartley, RI Gafni, KL Roszko, SM Brown, LF de Castro, A Saikali, ... Journal of Bone and Mineral Research 37 (11), 2174-2185, 2020 | 10 | 2020 |
Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor Induced Osteomalacia IR Hartley, KL Roszko, X Li, K Pozo, J Streit, J Rivero, MT Magone, ... Journal of Bone and Mineral Research Plus 6 (8), e10661, 2022 | 8 | 2022 |
Ocular adverse effects of infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor MT Magone, IR Hartley, E Fitzgibbon, R Bishop, M Arango, S Moran, ... Ophthalmology 128 (4), 624-626, 2021 | 8 | 2021 |
Consideration of ICD-9 code-derived disease-specific safety indicators in CKD IR Hartley, JS Ginsberg, CJ Diamantidis, M Zhan, L Walker, GB Rattinger, ... Clinical Journal of the American Society of Nephrology 8 (12), 2123-2131, 2013 | 6 | 2013 |
The effects of Encaleret (CLTX-305) on mineral physiology in autosomal dominant hypocalcemia type 1 (ADH1) demonstrate proof-of-concept: early results from an ongoing phase 2b … RI Gafni, IR Hartley, KL Roszko, EF Nemeth, KA Pozo, R Sani-Grosso, ... Journal of the Endocrine Society 5 (Supplement_1), A269-A269, 2021 | 5 | 2021 |
Burosumab for Tumor‐Induced Osteomalacia: Not Enough of a Good Thing IR Hartley, MT Collins Journal of Bone and Mineral Research 36 (12), 2453-2454, 2020 | 5 | 2020 |
SUN-364 enthesophytes are a common feature of FGF23-mediated hypophosphatemia due to tumor-induced osteomalacia RI Gafni, EJ Spector, IR Hartley, B Redd, GL Mitnik, MT Collins Journal of the Endocrine Society 4 (Supplement_1), SUN-364, 2020 | 2 | 2020 |
Efficacy and safety of encaleret in autosomal dominant hypocalcemia type 1 RI Gafni, IR Hartley, KL Roszko, EF Nemeth, KA Pozo, E Lombardi, ... New England Journal of Medicine 389 (13), 1245-1247, 2023 | 1 | 2023 |
Encaleret (CLTX-305) normalized mineral homeostasis parameters in patients with autosomal dominant hypocalcemia type 1: Results over 12 months in a phase 2 study (NCT04581629) M Collins, I Hartley, K Roszko, E Nemeth, K Pozo, W Boykin, A Mathew, ... Endocrine Abstracts 90, 2023 | 1 | 2023 |
Effects of Encaleret on Corrected QT Interval in Autosomal Dominant Hypocalcemia Type 1: Early Results From an Ongoing Phase 2b, Open-Label, Dose-Ranging Study I Hartley, R Gafni, K Roszko, K Pozo, MT Collins, E Nemeth, ... Circulation 144 (Suppl_1), A14476-A14476, 2021 | 1 | 2021 |
A Phase 2B, Open-Label, Dose-Ranging Study of Encaleret (CLTX-305) in Autosomal Dominant Hypocalcemia Type 1 (ADH1) RI Gafni, IR Hartley, KL Roszko, EF Nemeth, KA Pozo, R Sani-Grosso, ... Journal of the Endocrine Society 5 (Suppl 1), A253, 2021 | 1 | 2021 |